
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc exhibits a promising outlook as its innovative Enhanced Delivery Oligonucleotide (EDO) platform has demonstrated superior splicing correction rates, achieving a notable 53.7%—significantly higher than competitors. The ongoing anticipation of multi-dose data from its clinical pipeline is expected to highlight substantial potential for positive risk/benefit profiles, potentially driving further investor interest and stock value. With shares currently trading around $4, there is a considerable market opportunity as favorable clinical outcomes could translate into both improved therapy effectiveness and enhanced market capitalization for the company.
Bears say
PepGen Inc.'s recent updates indicate a $1 decrease in its target price to $8 per share, highlighting challenges in maintaining investor confidence despite the company delivering promising clinical data. The company's market cap appears significantly undervalued compared to competitors, which raises concerns about its future execution and the ability to meet or exceed market expectations. Additionally, potential difficulties in accessing capital markets could hinder the development of its pipeline products, increasing the risk of delays or termination of critical campaigns.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares